Literature DB >> 2901289

Predicting return to work after acute myocardial infarction. Significance of clinical data, exercise test variables and beta-blocker therapy.

P K Rønnevik1.   

Abstract

Among 66 full-time employed men surviving an acute myocardial infarction (AMI) and participating in the Norwegian postinfarction study with timolol, 50 (75.7%) resumed their previous work within 12 months, and 16 (24.3%) retired. Stepwise logistic regression analysis of clinical data and of results from an exercise test 3 months post AMI revealed the following factors of independent predictive value for enhanced return to work: previous labor characterized as light or moderately heavy (p = 0.001), low age at the time of infarction (p = 0.001), timolol treatment (p = 0.009), ability to stop smoking post AMI (p = 0.006), and a high exercise capacity on the exercise test (p = 0.016). It is concluded that the clinical history and an exercise test 3 months after AMI can identify patients who are more likely to resume work, and that post-AMI beta-blocker treatment with timolol and ability to stop smoking are predictive of an enhanced return to work.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2901289     DOI: 10.1159/000174377

Source DB:  PubMed          Journal:  Cardiology        ISSN: 0008-6312            Impact factor:   1.869


  3 in total

1.  Who retires early and why? Determinants of early retirement pension among Danish employees 57-62 years.

Authors:  Thomas Lund; Ebbe Villadsen
Journal:  Eur J Ageing       Date:  2005-11-29

2.  Cardiopulmonary exercise testing is predictive of return to work in cardiac patients after multicomponent rehabilitation.

Authors:  Annett Salzwedel; Rona Reibis; Karl Wegscheider; Sarah Eichler; Hermann Buhlert; Stefan Kaminski; Heinz Völler
Journal:  Clin Res Cardiol       Date:  2015-09-16       Impact factor: 5.460

3.  Predicting return to work after acute myocardial infarction: Socio-occupational factors overcome clinical conditions.

Authors:  Mariarita Stendardo; Melissa Bonci; Valeria Casillo; Rossella Miglio; Giulia Giovannini; Marco Nardini; Gianluca Campo; Alessandro Fucili; Piera Boschetto
Journal:  PLoS One       Date:  2018-12-13       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.